Fig. 4 | Scientific Reports

Fig. 4

From: Management of COVID-19 associated coagulopathy in critically ill patients and the risk of acquired von willebrand syndrome

Fig. 4

Time course of VWF multimer analysis for representative patients from ECMO and non-ECMO groups.

HMW VWF multimers were present to the same extent in both the ECMO and non-ECMO groups at P-1. The ratio of HMW VWF multimers in the non-ECMO group thereafter remained almost unchanged over time, while the ratio of HMW VWF multimers in the ECMO group gradually decreased and shifted toward LMW VWF multimers after the start of ECMO (P-2 and P-3).

Point 1 (P-1): day 1 (at intensive care unit admission in both groups, and before starting vvECMO in the ECMO group), Point 2 (P-2): day 3 or 4 (ECMO group: third day after starting vvECMO, non-ECMO group: day 3), and Point 3 (P-3): day 6 to 7 (ECMO group: sixth day after starting vvECMO, non-ECMO group: day 6 or 7).

VWF, von Willebrand factor; ECMO, extracorporeal membrane oxygenation; HMW, high molecular weight; LMW, low molecular weight; IMW, intermediate molecular weight.

Back to article page